Nykode Therapeutics ASA — Director's Dealing 2021

Jun 14, 2021

Grant of Share Options

Oslo, Norway, June 14, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced that 100,000 share options have been granted to Katrine Husum in connection with her appointment as Director Project and Alliance Management. The share options will have a strike price of NOK 69.58 per share, vest in four equal tranches on February 1 each year and expire February 1, 2026. After the award of the share options, Katrine Husum holds a total of 100,000 share options and 0 shares.

About Vaccibody

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody's vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and longlasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung- , head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the head & neck. Further, the Company has collaborations with Roche and Nektar Therapeutics within oncology.

Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications, including its second-generation COVID-19 vaccine program, VB10.COV2.

Vaccibody's shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at http://www.vaccibody.com

Contact for Vaccibody:

CEO Michael Engsig Vaccibody AS Cell: +45 6173 1509 mengsig@vaccibody.com

1	Details of the person discharging managerial responsibilities
a)	Name	Katrine Husum
b)	Position	Director Project and Alliance Management
2	Reason for notification
a)	Initial notification/ Amendment	Initial
3	Details of issuer
a)	Name	Vaccibody AS
b)	LEI	254900UKQHWYZJD22017
4	transactions have been conducted	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where
a)	Description of the financial instrument, type of instrument	Options with shares in Vaccibody AS (ISIN: NO0010714785) as underlying
b)	Nature of the transaction	Granting of stock options to employee as part of remuneration package
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	100,000
d)	Aggregated information	Price(s)	Volume(s)
	-Average price and	0	100,000
	aggregated volume
e)	Date of the transaction	14.06.2021
f)	Place of the transaction	Outside of trading venue